Literature DB >> 15643295

Familial Mediterranean fever (FMF) in Turkey: results of a nationwide multicenter study.

Mehmet Tunca1, Servet Akar, Fatos Onen, Huri Ozdogan, Ozgur Kasapcopur, Fatos Yalcinkaya, Ercan Tutar, Seza Ozen, Rezan Topaloglu, Engin Yilmaz, Mustafa Arici, Aysin Bakkaloglu, Nesrin Besbas, Tekin Akpolat, Ayhan Dinc, Eren Erken.   

Abstract

Familial Mediterranean fever (FMF) is an autosomal recessive disease that is prevalent among eastern Mediterranean populations, mainly non-Ashkenazi Jews, Armenians, Turks, and Arabs. Since a large proportion of all the FMF patients in the world live in Turkey, the Turkish FMF Study Group (FMF-TR) was founded to develop a patient registry database and analyze demographic, clinical, and genetic features. The cohort was composed of 2838 patients (mean age, 23.0 +/- 13.33 yr; range, 2-87 yr), with a male:female ratio of 1.2:1. There was a mean period of 6.9 +/- 7.65 years from disease onset to diagnosis; the period was about 2 years shorter for each decade since 1981. Ninety-four percent of patients were living in the central-western parts of the country; however, their familial origins (70% from the central-eastern and Black Sea regions) reflected not only the ongoing east to west migration, but also the historical roots of FMF in Turkey. Patients' clinical features included peritonitis (93.7%), fever (92.5%), arthritis (47.4%), pleuritis (31.2%), myalgia (39.6%), and erysipelas-like erythema (20.9%). Arthritis, arthralgia, myalgia, and erysipelas-like erythema were significantly more frequent (p < 0.001) among patients with disease onset before the age of 18 years. Genetic analysis of 1090 patients revealed that M694V was the most frequent mutation (51.4%), followed by M680I (14.4%) and V726A (8.6%). Patients with the M694V/M694V genotype were found to have an earlier age of onset and higher frequencies of arthritis and arthralgia compared with the other groups (both p < 0.001). In contrast to other reported studies, there was no correlation between amyloidosis and M694V homozygosity in this cohort. However, amyloidosis was still remarkably frequent in our patients (12.9%), and it was prevalent (27.8%) even among the 18 patients with a disease onset after age 40 years. Twenty-two patients (0.8%) had nonamyloid glomerular diseases. The high prevalence of vasculitides (0.9% for polyarteritis nodosa and 2.7% for Henoch-Schonlein purpura) and high frequency of pericarditis (1.4%) were striking findings in the cohort. Phenotype II cases (those patients with amyloidosis as the presenting or only manifestation of disease) were rare (0.3% or less). There was a high rate of a past diagnosis of acute rheumatic fever, which suggested a possible misdiagnosis in children with FMF presenting with recurrent arthritis. To our knowledge, this is the largest series of patients with FMF reported from 1 country. We describe the features of the disease in the Turkish population and show that amyloidosis is still a substantial problem.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15643295     DOI: 10.1097/01.md.0000152370.84628.0c

Source DB:  PubMed          Journal:  Medicine (Baltimore)        ISSN: 0025-7974            Impact factor:   1.889


  202 in total

1.  Mediterranean fever (MEFV) gene mutation frequency is not increased in adults with rheumatic heart disease.

Authors:  Ismail Simsek; Cem Koz; Nurcan Basar; Ismail Sari; Hakan Erdem; Salih Pay; Bunyamin Kisacik; Muhterem Bahce; Ayhan Dinc
Journal:  Clin Rheumatol       Date:  2010-07-20       Impact factor: 2.980

Review 2.  Genetically defined autoinflammatory diseases.

Authors:  A A de Jesus; R Goldbach-Mansky
Journal:  Oral Dis       Date:  2016-04-14       Impact factor: 3.511

3.  Familial Mediterranean fever in Syrian children: phenotype-genotype correlation.

Authors:  Rami A Jarjour; Sumaya Al-Berrawi
Journal:  Rheumatol Int       Date:  2014-08-24       Impact factor: 2.631

4.  The importance of Mediterranean fever gene in familial Mediterranean fever.

Authors:  Demet Yalçın Kehribar; Metin Özgen
Journal:  Eur J Rheumatol       Date:  2020-07-21

5.  Clinical and genetic features of hereditary periodic fever syndromes in Hispanic patients: the Chilean experience.

Authors:  Cristian Vergara; Arturo Borzutzky; Miguel A Gutierrez; Sergio Iacobelli; Eduardo Talesnik; María E Martinez; Lilith Stange; Javier Basualdo; Viviana Maluje; Renato Jimenez; Roberto Wiener; Javier Tinoco; Elena Jarpa; Juan I Aróstegui; Jordi Yagüe; Manuel Alvarez-Lobos
Journal:  Clin Rheumatol       Date:  2012-01-28       Impact factor: 2.980

Review 6.  The myths we believed in familial Mediterranean fever: what have we learned in the past years?

Authors:  Seza Ozen; Ezgi Deniz Batu
Journal:  Semin Immunopathol       Date:  2015-04-02       Impact factor: 9.623

7.  Decrease in the rate of secondary amyloidosis in Turkish children with FMF: are we doing better?

Authors:  Victoria Akse-Onal; Erdal Sağ; Seza Ozen; Aysin Bakkaloglu; Nilgun Cakar; Nesrin Besbas; Safak Gucer
Journal:  Eur J Pediatr       Date:  2010-02-24       Impact factor: 3.183

8.  Frequency of functional gastrointestinal disorders in children with familial Mediterranean fever.

Authors:  Rabia Miray Kisla Ekinci; Sibel Balcı; Eray Akay; Gokhan Tumgor; Dilek Dogruel; Derya Ufuk Altintas; Mustafa Yilmaz
Journal:  Clin Rheumatol       Date:  2019-01-31       Impact factor: 2.980

9.  The spectrum of FMF mutations and genotypes in the referrals to molecular genetic laboratory at Kirikkale University in Turkey.

Authors:  Aysen Gunel-Ozcan; Derya Beyza Sayin; Emine Dibek Misirlioğlu; Sefa Güliter; Fahri Yakaryilmaz; Cuneyt Ensari
Journal:  Mol Biol Rep       Date:  2008-04-04       Impact factor: 2.316

10.  Screening of common and novel familial mediterranean fever mutations in south-east part of Turkey.

Authors:  Serdar Oztuzcu; Mustafa Ulaşlı; Sercan Ergun; Yusuf Ziya Iğci; Mehri Iğci; Recep Bayraktar; Gülper Nacarkahya; Ali Tamer; Muammer Ozgür Cevik; Ecir Ali Cakmak; Ahmet Arslan
Journal:  Mol Biol Rep       Date:  2014-01-28       Impact factor: 2.316

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.